stemgent
STEMCELL Technologies Applauds Nature Protocol Article Published by the Institut Pasteur
Publication describes the use of RoboSep® to isolate CD4+ and CD8+ T cells.
St. Jude Scientists Develop new Genomics-Based Approach to Understand the Origin of Cancer Subgroups
Unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor.
Regenerative Medicine Releases Special Focus Issue on Human iPS Cells
The July 2010 issue will provide an exclusive focus on Cellular Reprogramming and Induced Pluripotent Stem Cells.
International Stem Cell Institute Launches Customized Stem Cell Therapy Treatments for Cerebral Palsy
Unprecedented stem cell treatments providing new hope for children with CP.
FOXP3 Gene Expression in Multiple Sclerosis patients before and after Mesenchymal Stem Cell therapy
Tehran University of Medical Sciences,University of Tehran

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the CNS. No successful treatment for MS, but one therapeutic strategy in research is the use of bone marrow-derived mesenchymal stem cells (MSC). We studied a group of MS patients who underwented MSCs, assayed for expression of a transcription factor, FOXP3, as a specific marker of MS amelioration in peripheral blood. qRT-PCR on PBMCs showed higher FoxP3 levels.
Three-Dimensional Cell Culture Within A Biomimetic Hydrogel Based On Chitosan And Hyaluronan
University of Minnesota

A growing demand for study of cells within biologically realistic, in vitro, microenvironments requires a paradigm shift in cell culture technology: from cell culture on 2-D, rigid substrata to cell growth within a 3-D space, defined by malleable materials composed of biologically “smart” compounds.1, 2

Therapeutic issues addressed by tissue engineering and regenerative medicine require similar materials, customized for human application in a wide variety of treatment circumstances: ranging
Post-doctoral position at INRA (France)
INRA
An 18-month post-doctoral position is available at INRA Clermont-Ferrand-Theix (France).The position is opened to both French and foreign applicants.
Engineer Technician, Fayetteville, Arizona, USA
SFC-Fluidics
SFC Fluidics is looking to hire a highly motivated, detail-oriented engineer technician.

oral communication skills . Experience with GMP and GLP desired
Computational Medicinal Chemistry Post-Doc Position, Siena, Italy
University of Siena
NatSynDrugs Is Seeking Candidates For a Computational Medicinal Chemistry Post-Doc Position
Program Development Manager, LasX Industries, MN, USA
LasX Industries
The position of Program Development Manager assumes the lead role for developing production processes for targeted programs, primarily in the micro-fluidics market.
Automation Engineer, Metabolism, Agios Pharmaceuticals, Cambridge, MA, USA
Agios Pharmaceuticals
With new research showing that cancer cells become addicted to using more nutrients than normal cells to promote their rapid growth, there is an unprecedented opportunity to create a new class of oncology therapeutics that target a fundamental and ubiquitous mechanism in cancer cells. The intersection of these two fields of research - cancer and metabolism- represents an important and novel approach to treating cancer.
Senior Scientist, Metabolism
Agios
Agios Pharmaceuticals is seeking a PhD Scientist to join a team that is building and applying a state-of-art approach to investigate the intersection of cancer cell biology and metabolism.
Cancer Genomics & Cancer Mutations
02 August 2010 - 04 August 2010

Personalizing Cancer Medicine: Strategies for Drug and Diagnostic Development
Learn more about:
• New approaches for targeting cancers and personalizing treatment regimens
• Exploiting the expressed tumor genome and DNA structure/sequence
• Breaking news from cancer genome consortia and clinical projects
Register at www.IBCLifeSciences.com/cancergenomics, save 20% off standard rates, use priority code: D10201TN.
Cancer Stem Cells & the Tumor Microenvironment
02 August 2010 - 04 August 2010

Exploiting CSC's, Inflammation and Stromal Support of Tumors for Therapeutic Intervention
Learn more about:
• Therapeutics targeting the inflammatory component of tumors
• Data from cancer stem cell-targeted drugs in development
• New insights on stromal support of tumors and the tumor microenvironment
Register at www.IBCLifeSciences.com/cancermicro, save 20% off standard rates, use priority code: D10201TN.
  
Adult Stem Cells and iPSCs 2010
Select Biosciences Ltd

This market report from Select Biosciences comprehensively addresses the technology and market landscape governing adult stem cells as well as induced pluripotent stem cells (iPSCs).
Stem Cells Market Trends 2010: Drug Discovery/Toxicity Screening and Regenerative Medicine
Select Biosciences Ltd

This market trends report from Select Biosciences presents the results from our latest industry tracking completed in March 2010. The data presented herein are based on primary market surveys from a worldwide respondent pool of industry participants active in the stem cells field.
Stem Cell-Derived Human Neurons in CNS Drug Discovery
Molecular Devices

Central nervous system (CNS) disorders affect many people worldwide. To increase the quality and number of drugs available for treatments of CNS disorders such as Alzheimer’s disease, schizophrenia and anxiety, the success rate of CNS drug discovery programs must be improved. The challenge in drug discovery is to develop more relevant assay systems to identify lead compounds for further development. Cell-based screening assays currently used for CNS drug discovery and development involve primary